Sunshine Biopharma Inc
OTC:SBFM

Watchlist Manager
Sunshine Biopharma Inc Logo
Sunshine Biopharma Inc
OTC:SBFM
Watchlist
Price: 0.89 USD -0.27% Market Closed
Updated: May 17, 2024
Section:
 

Wall Street
Price Targets

SBFM Price Targets Summary
Sunshine Biopharma Inc

Wall Street analysts forecast SBFM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SBFM is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.

SBFM Lowest Forecast
Wall Street Target
3.03 USD
240% Upside
SBFM Average Forecast
Wall Street Target
3.06 USD
244% Upside
SBFM Highest Forecast
Wall Street Target
3.15 USD
254% Upside
Lowest
Price Target
3.03 USD
240% Upside
Average
Price Target
3.06 USD
244% Upside
Highest
Price Target
3.15 USD
254% Upside
Sunshine Biopharma Inc Competitors:
Price Targets
BCYC
Bicycle Therapeutics PLC
99% Upside
PHARM
Pharming Group NV
116% Upside
N
NYKD
Nykode Therapeutics ASA
173% Upside
INCY
Incyte Corp
30% Upside
BCYC
Bicycle Therapeutics PLC
99% Upside
PHARM
Pharming Group NV
116% Upside
N
NYKD
Nykode Therapeutics ASA
173% Upside
INCY
Incyte Corp
30% Upside
VRTX
Vertex Pharmaceuticals Inc
8% Upside
ZYME
Zymeworks Inc
57% Upside
ELDN
Eledon Pharmaceuticals Inc
468% Upside
ITOS
Iteos Therapeutics Inc
107% Upside

Revenue
Forecast

Revenue Estimate
Sunshine Biopharma Inc

The compound annual growth rate of Sunshine Biopharma Inc's revenue for the next 2 years is 106%.

N/A
Past Growth
106%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Sunshine Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Sunshine Biopharma Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
SBFM intrinsic value, competitors valuation, and company profile.
DCF Valuation
SBFM stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SBFM stock valuation using valuation multiples.
Wall Street Estimates
SBFM price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SBFM stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SBFM's stock price target?
Price Target
3.06 USD

According to Wall Street analysts, the average 1-year price target for SBFM is 3.06 USD with a low forecast of 3.03 USD and a high forecast of 3.15 USD.

What is Sunshine Biopharma Inc's Revenue forecast?
Projected CAGR
106%

The compound annual growth rate of Sunshine Biopharma Inc's revenue for the next 2 years is 106%.

ALPHA SPREAD
Join more than 137,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.